您现在位置:首页 > 公司概况

辽宁博鳌生物制药有限公司成立于2010年,坐落在国家辽宁(本溪)生物医药产业基地本溪经济技术开发区,是以研发、生产胰岛素系列产品为一体的现代化生物制药企业。占地面积35000平方米、建筑面积20000平方米,现有固定资产近两亿元。

辽宁博鳌生物制药有限公司始终以人类健康为宗旨,以服务社会、回报社会为己任。力求在生物制药领域走出一条创新之路。在不断引进高科技人才的前提下,已研发出国际领先的基因重组蛋白质药物重组人胰岛素,及其长效类似物甘精胰岛素、速效类似物门冬胰岛素。

辽宁博鳌生物制药有限公司依靠政策优势、区域优势,以及现有的人才、科技优势,在短时间内使企业逐步发展成技术密集、管理规范、产品一流、质量可靠地现代化制药企业。

辽宁博鳌生物制药有限公司自主研发生产的胰岛素类系列产品与国际国内市场销售的同类产品相比,具有以下特点:
1.
纯度高,杂质种类和含量不高于市场销售的同类产品。
2. 质量标准高,满足欧盟、美国等多个现行药典标准。
3. 生产工艺节能环保,独特的生产工艺,减少了污染物排放,提高了产品收率。
LiaoNingBoao Biological Pharmaceutical Co.,Ltd founded in 2010,is located in the Chinesebiologically pharmaceutical industrial base,EconomicTechnological Development District,Benxi,Liaoning. Boao is a research anddevelopment,the production of insulin products and APIs for the integration ofmodern biological science and technology enterprise.It covers an area of 35,000square meters and its area of structure is 20,000 square meters,its fixedassets is nearly 200 million Yuan.

LiaoNingBoao Biological Pharmaceutical Co.,Ltd is always working for human health and servingfor the society,and take repaying society as our responsibility.We are strivingfor walking out an innovation road in the biological pharmaceutical field.Under the premise of introducing of high-tech talents, ourcompany has been developed the international advanced gene recombinant protein pharceutical:recombinant human insulin and its long-acting analogue insulin glarginequick-actinganalogue insulin aspart.

LiaoNingBoao Biological Pharmaceutical Co.,Ltd relys on the policy advantages andregional and exsisting talents and technological advantages to make itself developinto a modern technology-intensive  pharceutical enterprise which has standardizedmanagement and produce first-rate and reliable quality products.

Compared with the international and domesticmarket, our series of independent research and development insulin products hasthe following features:

1. Thepurity is high. Our products’ impurities spots are not higher than the similarproducts in the market

2. Thequality standard is high. It meets European Union and the United States’ multiplepharmacopoeia criterion in force.

3. Themanufacturing technique is saving energy and protecting environment.The unique techniquereduces the pollutant discharge and increases the production yeild at the sametime.